CureMatch
×
  • Physicians
  • Patients
  • Employers
  • About Us
  • News
    • CureMatch News
    • Validation and Research
    • Events & Conferences
  • Contact
  • Login
Ally Perlina

Ally Perlina

CHIEF SCIENCE OFFICER

Ally Perlina is a proven executive leader who has dedicated nearly two decades of industry experience to solving challenging problems in precision medicine, health-tech, and pharmaceutical fields to improve human health with molecular-level personalization. She is a visionary innovator with a track record of translating complex data into actionable insights delivered as scalable AI products by integrating analytics with systems biology and knowledge management techniques.

As Chief Translation Science Office (CTSO) of Viome, Ally developed unique methodology for automated pathway analysis personalizing nutraceuticals at scale. Previously, at Human Longevity, Inc. (HLI), co-founded by Craig Venter, Ally spearheaded the Comprehensive Cancer Program creating novel analytics for clinical decision support. At tumor boards, she provided mechanistic rationale for drug and trial prioritization. Ally’s experience also includes working with top pharma at a systems biology startup acquired by Thomson Reuters, researching cancer at SBP, working at a CLIA lab acquired by Quest, and focusing on clinical genomics of brain tumors in her graduate training at the UCLA Ph.D. program in Human Genetics where she also earned her M.S. degree. Ally received her B.S. in Biochemistry and Cell Biology from UCSD. She is a published author and an inventor on several patents.

logo

+1 (858) 284-0488

FAX: +1 (858) 430-5813

Quick Links

  • Physicians
  • About CureMatch
  • News and Latest Posts
    • CureMatch News
    • Validation and Case Studies
    • Events and Conferences
  • Contact Us
  • FAQ

Latest News and Results

  • CureMatch Granted CPT® Code by American Medical Association for its Algorithmic Cancer Therapy Ranking Service Jan 4

    Oncologists will be able to submit claims to payers using a Category III CPT code,...

  • CureMatch CEO Navid Alipour named a Top 50 Honoree Leader of Influence in Life Science by San Diego Business Journal Jul 26

    Congratulations to CureMatch CEO Navid Alipour for being named a Top Leader of Influence in...

  • CureMatch Announces the Addition of John S. Link, Jordan Shlain and Greg Simon to Advisory Board Jul 21

    Dr. Link, Dr. Shlain and Mr. Simon all bring deep entrepreneurial experience in the medical...

© 2021 CureMatch, Inc. CureMatch is a registered trademark.
Terms of Use | Privacy Policy | HIPAA Notice

We’d like to send you a CureMatch Sample Analysis

 

Sample Analysis Download Form

  • This field is for validation purposes and should be left unchanged.

 

We value and respect your privacy and will not publish, share, or sell your contact information.

View Privacy Policy

Some pages of this website are intended for healthcare professionals

This webpage is strictly reserved for healthcare professionals. Please confirm that you are a healthcare professional.

Otherwise, you will be redirected to the institutional part of this website.

Thank you for your understanding.

I am a healthcare professionalI am not a healthcare professional

Get ready to utilize the latest genomics data in your practice

Rank the most promising systemic therapies for your patients

Do you need to filter out those therapies with poor outcomes

Sort through 4.5 million expertly curated combinations of drugs

Compute your own drug choices alongside CureMatch data